Nursing home residents with dementia who use average doses of selective serotonin reuptake inhibitors (SSRIs) are three times more likely to have a fall resulting in injury compared with those who don’t use SSRIs, according a study published online January 18 in the British Journal of Clinical Pharmacology
Nursing home residents with dementia who use average doses of selective serotonin reuptake inhibitors (SSRIs) are 3 times more likely to have a fall resulting in injury compared with those who don’t use SSRIs, according a study published online January 18 in the British Journal of Clinical Pharmacology.
Even at low doses, SSRIs are associated with an increased risk of a fall resulting in injury and the risk increases with higher doses, according to researchers led by Carolyn S. Sterke, MSc, from Erasmus University Medical Center, Rotterdam, the Netherlands.
SSRIs have been shown to be associated with an increased risk of falling, the authors wrote. “In nursing homes, many patients with dementia are given SSRIs as a treatment for depression. In this group, however, the possible risk of injurious falls by treatment dosage is not known,” they commented.
To determine whether a dose-response relationship exists between the use of SSRIs and falls resulting in injury in nursing home residents with dementia, the researchers recorded daily drug use and falls for 248 nursing home residents with dementia from January 1, 2006, through January 1, 2008.
Drug-use data was abstracted from a prescription database, and information on falls and subsequent injuries was culled from a standardized incident report system.
The data showed that 152 (61.5%) of the residents sustained 683 falls, corresponding to 2.9 falls per person-year. Thirty-eight residents (15.4%) fell only once; however, 114 (46.2%) residents fell frequently. Of the 220 (32.2%) falls that resulted in injury, 21 were fractures, and 198 were Injuries other than fractures (graze, open wound, sprain, bruise, and swelling injuries). One person died.
The risk of having a fall resulting in injury increased significantly, with 31% occurring at 0.25 of the defined daily dose (DDD) of a SSRI, 73% at 0.50 DDD, and 198% at 1.00 DDD (HR=2.98; 95% CI, 1.94-4.57). The risk also increased with age (HR=.05; 95% CI, 1.01-1.09), the use of antipsychotics (HR=1.76; 95% CI, 1.18-2.63), and antidepressants (HR=2.58; 95% CI, 1.57-4.24).
Falls are a major health problem in nursing home residents with dementia. “The results of this study lend support to the consideration that new treatment protocols might be needed that take into account the dose-response relationship between SSRIs and injurious falls,” the authors concluded.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.